CEO Ken d'Entremont highlighted the successful FDA approval of GRAFAPEX, the branded name for treosulfan for injection in the U.S., which holds Orphan Drug Designation, ensuring at least seven years ...
Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.
Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here.